From: Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review
Adverse effects | Antiretroviral drugs | Antituberculosis drugs |
---|---|---|
Gastrointestinal disturbance and/or pain | AZT, ddI, PIs | RIF, INH, PZA, ethionamide, PAS, clofazamine, linezolid |
Liver injury | NVP, EFV, PIs, NRTIsa | RIF, INH, PZA and many second line drugs including ethionamide, fluoroquinolones, PAS |
Peripheral neuropathy | D4T, ddI | INH, ethionamide, terizidone/cycloserine, linezolid |
Neuropsychiatric | EFV | Terizidone/cycloserine, ethionamide, fluoroquinolones, INH |
Renal impairment | TDF | Aminoglycosides and capreomycin |
Rash | NVP, EFV, ABC | Rifampicin, INH, PZA, ethambutol, streptomycin and many second line drugs including fluoroquinolones, PAS, clofazamine |
Blood dyscrasias | AZT, 3TC | Linezolid, rifabutin, INH, rifampicin |
Cardiac conduction abnormalities | PIs | Bedaquiline, fluoroquinolones, clofazamine |
Pancreatitis | D4T, ddI | Linezolid |
Lactic acidosis | D4T, ddI | Linezolid |